Noubar Afeyan's Moderna has begun a late-stage COVID-19 vaccine trial involving about 30,000 adults who have not tested positive.
Ahead of the opening of trading, shares in the Massachusetts-based company rose 11 percent to $ 81.31, Voice of America reported.
These are the first tests being carried out as part of the government's program, which aims to accelerate the development, production, and distribution of drugs and vaccines for COVID-19.
The US government has allocated about a billion dollars to the Moderna project and has selected a vaccine developed by the company for large-scale human trials.
According to the company, the main goal of the study is to prevent symptomatic manifestations of the disease.